z-logo
open-access-imgOpen Access
Metformin versus laparoscopic unilateral ovarian drilling in clomiphene resistant women with polycystic ovary syndrome
Author(s) -
Ibrahim Abd Elgafor El Sharkwy
Publication year - 2013
Publication title -
middle east fertility society journal/middle east fertility society journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.322
H-Index - 18
eISSN - 2090-3251
pISSN - 1110-5690
DOI - 10.1016/j.mefs.2012.12.008
Subject(s) - medicine , polycystic ovary , metformin , miscarriage , ovulation , pregnancy rate , pregnancy , randomized controlled trial , gynecology , obstetrics , urology , hormone , insulin resistance , insulin , biology , genetics
Objectives: To compare the hormonal-metabolic profiles and reproductive outcomes between women receiving metformin and women undergoing unilateral ovarian drilling in clomiphene citrate(CC) resistant patients with polycystic ovary syndrome (PCOS)Design: Non randomized controlled trial.Setting: Obstetrics and Gynecology department, Faculty of medicine, Zagazig University, Egypt.Methods: A total of 120 patients were divided into group 1(n=58) who received metformin therapy and group 2 (n=62) who underwent unilateral ovarian drilling. Hormonal-metabolic profiles changes after treatment were reported and reproductive outcomes were compared between both groups.Main outcome: FSH and LH were reduced significantly in unilateral drilling group (P=<0.001and 0.001), while there was significant improvement in testosterone level , fasting insulin, fasting glucose to insulin ratio and homeostasis model assessment index in metformin therapy group. Pregnancy and ovulation rates were higher after unilateral drilling with significant difference (P=0.048 and 0.004). No significant difference in early miscarriage rate between both groups (P=0.51).Conclusion: Unilateral LOD was associated with greater ovulation and pregnancy rates than metformin in women with PCOS who did not conceive with CC

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here